[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. Yoon HS, Lee JH, Moon HN, Seo JJ, Im HJ, Goo HW: Successful treatment of retroperitoneal infantile hemangioendothelioma with Kasabach-Merritt syndrome using steroid, alpha-interferon, and vincristine. J Pediatr Hematol Oncol; 2009 Dec;31(12):952-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of retroperitoneal infantile hemangioendothelioma with Kasabach-Merritt syndrome using steroid, alpha-interferon, and vincristine.
  • Infantile hemangioendothelioma (IHE) is a rare benign vascular tumor with potentially life-threatening complications.
  • Because of the slow and unpredictable response to treatment with using a single drug in critically ill patients, there is a tendency to administer drugs in combination to treat this disease.
  • [MeSH-major] Disseminated Intravascular Coagulation / drug therapy. Hemangioendothelioma / drug therapy. Interferon-alpha / therapeutic use. Methylprednisolone / therapeutic use. Retroperitoneal Neoplasms / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Diagnosis, Differential. Drug Therapy, Combination. Female. Humans. Infant, Newborn. Syndrome. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875968.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 5J49Q6B70F / Vincristine; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


2. Durieu C, Bayle-Lebey P, Gadroy A, Loche F, Bazex J: [Intravascular papillary endothelial hyperplasia: multiple lesions appearing in the course of treatment with interferon beta]. Ann Dermatol Venereol; 2001 Dec;128(12):1336-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Intravascular papillary endothelial hyperplasia is a benign and rare vascular lesion.
  • DISCUSSION: Intravascular papillary endothelial hyperplasia is a benign and rare vascular lesion usually presenting as a simple nodule.
  • Intravascular papillary endothelial hyperplasia is divided into two groups: a pure form occurring within a dilated vessel and a mixed form appearing in benign vascular lesions.
  • [MeSH-major] Endothelium, Vascular / drug effects. Hemangioendothelioma / chemically induced. Interferon-beta / adverse effects. Multiple Sclerosis, Chronic Progressive / drug therapy. Skin Neoplasms / chemically induced
  • [MeSH-minor] Cell Division / drug effects. Hand / blood supply. Humans. Hyperplasia. Interferon beta-1a. Interferon beta-1b. Male. Middle Aged. Thrombosis / chemically induced. Thrombosis / pathology

  • Genetic Alliance. consumer health - Intravascular papillary endothelial hyperplasia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Interferon Beta-1b .
  • Hazardous Substances Data Bank. Interferon Beta-1a .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908138.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 145155-23-3 / Interferon beta-1b; 77238-31-4 / Interferon-beta; XRO4566Q4R / Interferon beta-1a
  •  go-up   go-down


3. Zhu Y, Cuevas IC, Gabriel RA, Su H, Nishimura S, Gao P, Fields A, Hao Q, Young WL, Yang GY, Boudreau NJ: Restoring transcription factor HoxA5 expression inhibits the growth of experimental hemangiomas in the brain. J Neuropathol Exp Neurol; 2009 Jun;68(6):626-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangiomas are angiogenesis-dependent benign vascular tumors that can rupture and cause intracranial hemorrhages.
  • Here, we investigated whether restoring expression of HoxA5 blocks hemangioma growth by transplanting mouse hemangioendothelioma endothelial cells (EOMA) or HoxA5-expressing EOMA cells into the brains of mice.

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1998 Jul 30;394(6692):485-90 [9697772.001]
  • [Cites] J Cell Biol. 1997 Oct 6;139(1):257-64 [9314544.001]
  • [Cites] Oncogene. 1999 Jul 22;18(29):4200-10 [10435633.001]
  • [Cites] J Cereb Blood Flow Metab. 2004 Nov;24(11):1280-7 [15545924.001]
  • [Cites] Stroke. 2005 Jul;36(7):1533-7 [15947259.001]
  • [Cites] Lymphat Res Biol. 2005;3(4):240-52 [16379594.001]
  • [Cites] J Atheroscler Thromb. 2005;12(6):330-7 [16394617.001]
  • [Cites] Angiogenesis. 2005;8(4):289-96 [16328158.001]
  • [Cites] J Craniofac Surg. 2006 Jul;17(4):767-71 [16877932.001]
  • [Cites] Cell Adh Migr. 2007 Oct-Dec;1(4):185-95 [19262140.001]
  • [Cites] J Invest Dermatol. 1999 Nov;113(5):782-7 [10571734.001]
  • [Cites] Biochem Pharmacol. 2000 Jan 1;59(1):47-53 [10605934.001]
  • [Cites] J Cell Biol. 2000 Jan 24;148(2):343-51 [10648567.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):965-76 [10702412.001]
  • [Cites] Circulation. 2000 Aug 22;102(8):898-901 [10952959.001]
  • [Cites] Circ Res. 2000 Nov 10;87(10):865-72 [11073881.001]
  • [Cites] J Clin Invest. 2001 Mar;107(6):665-6 [11254664.001]
  • [Cites] J Surg Res. 2001 Sep;100(1):46-56 [11516204.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:25-51 [11687483.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2271-80 [11733376.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7455-60 [12032304.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2099-109 [12466126.001]
  • [Cites] Stroke. 2003 Jan;34(1):177-86 [12511771.001]
  • [Cites] J Biochem Mol Biol. 2003 Jan 31;36(1):120-7 [12542982.001]
  • [Cites] Nat Med. 2003 Jun;9(6):677-84 [12778166.001]
  • [Cites] Circ Res. 2003 Oct 3;93(7):664-73 [12958144.001]
  • [Cites] Nat Rev Drug Discov. 2003 Oct;2(10):803-11 [14526383.001]
  • [Cites] Neurosurgery. 2003 Dec;53(6):1362-74; discussion 1374-6 [14633302.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4862-8 [14610084.001]
  • [Cites] Lab Invest. 1990 Aug;63(2):259-69 [2166185.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7291-5 [8041783.001]
  • [Cites] Biochem J. 1999 May 1;339 ( Pt 3):481-8 [10215583.001]
  • (PMID = 19458547.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R21 NS050668-02; United States / NINDS NIH HHS / NS / P01 NS044155-05; United States / NINDS NIH HHS / NS / R21 NS050668; United States / NINDS NIH HHS / NS / P01 NS044155; United States / NINDS NIH HHS / NS / R01 NS027713; United States / NINDS NIH HHS / NS / R01 NS27713; United States / NINDS NIH HHS / NS / NS044155-05; United States / NINDS NIH HHS / NS / NS027713-17; United States / NINDS NIH HHS / NS / R21 NS50668; United States / NINDS NIH HHS / NS / P01 NS44145; United States / NINDS NIH HHS / NS / R01 NS027713-17; United States / NINDS NIH HHS / NS / NS050668-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Hif1a protein, mouse; 0 / Homeodomain Proteins; 0 / Hoxa5 protein, mouse; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Lectins; 0 / Phosphoproteins; 0 / RNA, Messenger; 0 / Thrombospondins; 0 / thrombospondin 2
  • [Other-IDs] NLM/ NIHMS118393; NLM/ PMC2728585
  •  go-up   go-down


Advertisement
4. Arbiser JL, Bonner MY, Berrios RL: Hemangiomas, angiosarcomas, and vascular malformations represent the signaling abnormalities of pathogenic angiogenesis. Curr Mol Med; 2009 Nov;9(8):929-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiogenesis is a major factor in the development of benign, inflammatory, and malignant processes of the skin.
  • Hemangiomas, benign tumors of endothelial cells, represent the most common tumor of childhood.
  • Furthermore, we have studied malignant vascular tumors, including hemangioendothelioma and angiosarcoma and have shown distinct signaling abnormalities in these tumors.
  • The incidence of these tumors is expected to rise due to environmental insults, such as radiation and lumpectomy for breast cancer, dietary and industrial carcinogens (hepatic angiosarcoma), and chronic ultraviolet exposure and potential Agent Orange exposure.
  • [MeSH-minor] Animals. Humans


5. Arbiser JL, Weiss SW, Arbiser ZK, Bravo F, Govindajaran B, Caceres-Rios H, Cotsonis G, Recavarren S, Swerlick RA, Cohen C: Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy. J Am Acad Dermatol; 2001 Feb;44(2):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy.
  • BACKGROUND: Tumors of endothelium range from benign hemangiomas of infancy to highly malignant angiosarcomas of the elderly.
  • The biologic behavior of these lesions ranges from self-resolving, in the case of hemangiomas and pyogenic granulomas, to lethal metastatic neoplasms in the case of angiosarcoma.
  • Although the clinical outcomes of these diseases are easily distinguished, the biologic basis for these differences is not well understood.
  • OBJECTIVE: Our purpose was to examine expression of phosphorylated (activated) MAPK in hemangiomas of infancy, pyogenic granulomas, hemangioendotheliomas, and angiosarcomas to determine whether phosphorylated MAPK was expressed in endothelial tumors.
  • METHODS: Skin sections from benign and malignant endothelial tumors, including hemangioma of infancy, angiosarcoma, and infectious endothelial lesions (Kaposi's sarcoma, verruga peruana) were stained with an antibody specific for phosphorylated MAPK.
  • RESULTS: We demonstrated strong expression of phosphorylated MAPK in benign endothelial tumors, including capillary hemangioma of infancy and pyogenic granuloma, and greatly decreased expression in angiosarcoma.
  • In addition, infectious endothelial tumors stained strongly with this antibody, similar to benign tumors.
  • Immunohistochemistry for phosphorylated MAPK may help the pathologist distinguish benign from malignant endothelial processes and thus guide therapy.
  • [MeSH-minor] Granuloma, Pyogenic / drug therapy. Granuloma, Pyogenic / enzymology. Granuloma, Pyogenic / pathology. Hemangioendothelioma / drug therapy. Hemangioendothelioma / enzymology. Hemangioendothelioma / pathology. Hemangioma / drug therapy. Hemangioma / enzymology. Hemangioma / pathology. Hemangiosarcoma / drug therapy. Hemangiosarcoma / enzymology. Hemangiosarcoma / pathology. Humans. Immunohistochemistry. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / enzymology. Sarcoma, Kaposi / pathology. Skin Diseases / drug therapy. Skin Diseases / enzymology. Skin Diseases / pathology. Warts / drug therapy. Warts / enzymology. Warts / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11174372.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / KO8 AR02030; United States / NIAMS NIH HHS / AR / P30 AR 42687; United States / NIAMS NIH HHS / AR / R03AR44947
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


6. Jang HJ, Kim TK, Wilson SR: Imaging of malignant liver masses: characterization and detection. Ultrasound Q; 2006 Mar;22(1):19-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of microbubble contrast agents combined with specialized ultrasound (US) techniques has significantly expanded the role of US in the diagnosis of focal liver lesions based on their vascularity and specific enhancement features.
  • This pattern of complete rapid washout of metastases within the homogeneously enhanced background liver parenchyma can improve their detection and also improve differentiation from hepatocellular carcinoma or benign focal lesions.
  • All malignant lesions generally show negative enhancement or washout during the extended portal venous phase, and this pattern is useful to differentiate them from benign lesions.
  • Microbubble agents, confined to the intravascular space, may infrequently characterize malignancy by showing washout whereas CT or MR shows persistent enhancement due to interstitial distribution.
  • [MeSH-minor] Cholangiocarcinoma / ultrasonography. Hemangioendothelioma / ultrasonography. Humans. Lymphoma / ultrasonography. Microbubbles. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16641790.001).
  • [ISSN] 0894-8771
  • [Journal-full-title] Ultrasound quarterly
  • [ISO-abbreviation] Ultrasound Q
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 26
  •  go-up   go-down


7. Il'nitskiĭ AP, Ryzhova NI, Chudina AP, Nevzorova NI, Nekrasova EA: [Sodium nitrite-induced potentiation of spontaneous and 1,2-dimethylhydrazine-induced carcinogenesis in male mice F1 (C57 B1xCBA)]. Vopr Onkol; 2004;50(6):683-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Combined treatment with DMH and SN induced most of benign and malignant tumors (hepatic hemangioendothelioma, hepatocarcinoma, renal adenoma, etc.).
  • Our data confirmed the carcinogenic hazard of chronic exposure to SN which increased when in combination with that to a specific carcinogenic substance.
  • [MeSH-minor] Animals. Drug Synergism. Male. Mice. Mice, Inbred C57BL. Mice, Inbred CBA

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .
  • Hazardous Substances Data Bank. SODIUM NITRITE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755063.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Carcinogens; IX068S9745 / 1,2-Dimethylhydrazine; M0KG633D4F / Sodium Nitrite
  •  go-up   go-down


8. Biecker E, Fischer HP, Strunk H, Sauerbruch T: Benign hepatic tumours. Z Gastroenterol; 2003 Feb;41(2):191-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign hepatic tumours.
  • Benign hepatic tumours include a broad spectrum of regenerative and true neoplastic processes.
  • Cavernous haemangioma, the most common benign hepatic tumour, rarely needs treatment.
  • The main problem in angiomyolipoma is to distinguish it from malignant processes which do require treatment.
  • Therapeutic options are drug therapy or surgical resection.
  • Benign haemangioendothelioma of the infant is rare but may cause life-threatening complications.
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adenoma, Liver Cell / pathology. Adult. Aged. Diagnostic Imaging. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / pathology. Granuloma, Plasma Cell / diagnosis. Granuloma, Plasma Cell / pathology. Hemangioendothelioma / diagnosis. Hemangioendothelioma / pathology. Hemangioma, Cavernous / diagnosis. Hemangioma, Cavernous / pathology. Humans. Infant. Liver / pathology. Liver Regeneration / physiology. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12650132.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 138
  •  go-up   go-down


9. Chen CC, Kong MS, Yang CP, Hung IJ: Hepatic hemangioendothelioma in children: analysis of thirteen cases. Acta Paediatr Taiwan; 2003 Jan-Feb;44(1):8-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic hemangioendothelioma in children: analysis of thirteen cases.
  • Hepatic hemangioendothelioma (HE) is a tumor that presents in infancy and toddler.
  • HE appears to be a histologically benign tumor but may have a poor outcome because of complications.
  • For its management, steroid is a first-line medication.
  • [MeSH-major] Hemangioendothelioma / diagnosis. Liver Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12800377.001).
  • [ISSN] 1608-8115
  • [Journal-full-title] Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi
  • [ISO-abbreviation] Acta Paediatr Taiwan
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down






Advertisement